Dublin, May 23, 2025 (GLOBE NEWSWIRE) — The “Europe Precision Medicine Market: Focus on Ecosystem and Country – Analysis and Forecast, 2024-2034” report has been added to ResearchAndMarkets.com’s offering.
The Europe precision medicine market is projected to reach $118.79 billion by 2034 from $40.75 billion in 2024, at a CAGR of 11.29% during the forecast period of 2024-2034.
From one-size-fits-all therapies to highly customised therapeutic options, the precision medicine market in Europe is drastically changing the healthcare environment. More specialised methods of diagnosing and treating diseases have been made possible by technological advancements, especially in the fields of genomics, next-generation sequencing, and biomarker identification.
Personalised therapies are greatly improving patient outcomes in uncommon genetic disorders, cardiovascular diseases, and oncology. By promoting policies that are helpful and making significant investments in research and development, European governments have been instrumental in this change. While maintaining strict guidelines for patient privacy and data security, regulatory bodies are expediting the approval procedures for precision treatments.
The market is further bolstered by strategic alliances among pharmaceutical companies, biotech firms, and academic institutions, fostering an ecosystem of innovation and collaborative research. Digital health tools and artificial intelligence are increasingly integrated into clinical workflows, enhancing diagnostic accuracy and treatment customization. Despite challenges such as the high cost of advanced technologies, regulatory complexities, and the need for robust healthcare infrastructure, the momentum behind precision medicine remains strong. Europe’s commitment to personalized healthcare, underpinned by public funding and private investment, positions the region as a global leader in redefining clinical practices and delivering patient-centric care.
Market Trends, Drivers and Challenges of Europe Precision Medicine Market
Advances in genetics, artificial intelligence, and health technology that allow for individualised treatment options are driving a rapid evolution of the precision medicine business in Europe. Especially in oncology and uncommon disorders, the combination of next-generation sequencing and biomarker development is promoting early detection and focused treatments. The market is expanding thanks to government programs, more financing for healthcare innovation, and cooperative research activities. The market is expanding due to ageing populations, an increase in the prevalence of chronic diseases, and a need for more efficient treatment plans.
However, obstacles to wider adoption include expensive costs, intricate legal frameworks, and data privacy issues. It takes large infrastructure investments and patient education to incorporate precision medicine into traditional healthcare systems. Notwithstanding these obstacles, technological developments and strategic alliances between biotech, pharmaceutical, and academic organisations are opening the door to a more cohesive and effective precision medicine ecosystem, which will eventually lead to better patient outcomes and a shift in Europe towards individualised healthcare solutions.
Key Market Players
- Almac Group
- ANGLE plc
- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- QIAGEN N.V.
- bioMerieux SA
- Sanofi S.A.
- Randox Laboratories Ltd.
- GSK plc
- Novartis AG
- Menarini Silicon Biosystems
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 83 |
| Forecast Period | 2024 – 2034 |
| Estimated Market Value (USD) in 2024 | $40.75 Billion |
| Forecasted Market Value (USD) by 2034 | $118.79 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Europe |
Key Topics Covered:
1 Market Overview
1.1 Market Definition
1.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine
1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
1.4 Initiatives and Programs
1.5 Precision Medicine: Enabling Technologies and Applications
1.5.1 Innovators
1.5.1.1 3D DNA Printing
1.5.1.1.1 Introduction
1.5.1.1.2 Role of 3D DNA Printing
1.5.1.2 RNA-Seq
1.5.1.2.1 Introduction
1.5.1.2.2 Role of RNA-Seq in Precision Medicine
1.5.1.2.3 Key Players
1.5.1.3 4D Molecular Imaging
1.5.1.3.1 Introduction
1.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
1.5.1.3.3 Key Players
1.5.2 Early Adopters
1.5.2.1 CRISPR
1.5.2.1.1 Introduction
1.5.2.1.2 Role of CRISPR in Precision Medicine
1.5.2.1.3 Key Players
1.5.2.2 Blockchain
1.5.2.2.1 Introduction
1.5.2.2.2 Role of Blockchain in Precision Medicine
1.5.2.2.3 Key Players
1.5.2.3 Imaging Informatics
1.5.2.3.1 Introduction
1.5.2.3.2 Role of Imaging Informatics in Precision Medicine
1.5.2.3.3 Key Players
1.5.3 Early Majority
1.5.3.1 Artificial Intelligence (AI)
1.5.3.1.1 Introduction
1.5.3.1.2 Role of Artificial Intelligence in Precision Medicine
1.5.3.1.3 Key Players
1.5.3.2 Circulating Free DNA (cfDNA)
1.5.3.2.1 Introduction
1.5.3.2.2 Role of cfDNA in Precision Medicine
1.5.3.2.3 Key Players
1.5.3.3 Big Data
1.5.3.3.1 Introduction
1.5.3.3.2 Role of Big Data in Precision Medicine
1.5.3.3.3 Key Players
1.5.3.4 Next-Generation Sequencing (NGS)
1.5.3.4.1 Introduction
1.5.3.4.2 Role of NGS in Precision Medicine
1.5.3.4.3 Key Players
1.5.3.5 Health Informatics
1.5.3.5.1 Introduction
1.5.3.5.2 Role of Health Informatics in Precision Medicine
1.5.3.5.3 Key players
1.5.3.6 Bioinformatics
1.5.3.6.1 Introduction
1.5.3.6.2 Role of Bioinformatics in Precision Medicine
1.5.3.6.3 Key Players
1.5.4 Late Majority
1.5.4.1 Polymerase Chain Reactions (PCR)
1.5.4.1.1 Introduction
1.5.4.1.2 Role of PCR in Precision Medicine
1.5.4.1.3 Key players
1.5.4.2 Microarray
1.5.4.2.1 Role of Microarray in Precision Medicine
1.5.4.2.2 Key Players
2 Market: Industry Outlook
2.1 Precision Medicine Market: Ecosystem Analysis
2.2 Market Trends
2.2.1 Integrating Advanced Imaging for Enhanced Diagnostics and Treatment
2.2.2 Emergence of Biobanks as a Cornerstone of Precision Medicine
2.3 Industry Insights
2.3.1 Patent Analysis
2.3.2 Pipeline Analysis
2.3.3 Legal Requirements and Framework by the EMA
2.4 Ecosystem Summary
3 Region
3.1 Overview
3.2 Europe
3.2.1 Regional Overview
3.2.2 Driving Factors for Market Growth
3.2.3 Factors Challenging the Market
3.2.3.1 Europe Precision Medicine Market (by Ecosystem)
3.2.4 Germany
3.2.4.1 Germany Precision Medicine Market (by Ecosystem)
3.2.5 France
3.2.5.1 France Precision Medicine Market (by Ecosystem)
3.2.6 Italy
3.2.6.1 Italy Precision Medicine Market (by Ecosystem)
3.2.7 U.K.
3.2.7.1 U.K. Precision Medicine Market (by Ecosystem)
3.2.8 Spain
3.2.8.1 Spain. Precision Medicine Market (by Ecosystem)
3.2.9 Rest-of-Europe
3.2.9.1 Rest-of-Europe Precision Medicine Market (by Ecosystem)
4 Competitive Landscape
4.1 Competitive Landscape
4.1.1 Synergistic Activities
4.2 Company Profiles
4.2.1 Overview
4.2.2 Top Products/Services
4.2.3 Top Competitors
4.2.4 Analyst View
For more information about this report visit https://www.researchandmarkets.com/r/mo4hns
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- European Precision Medicine Market
